Lantern Pharma (NASDAQ: LTRN) reported second-quarter 2026 operational and financial results, showcasing significant progress in its AI-driven oncology pipeline and the establishment of Open Medicine AI (“OMAI”) as a separate company. The company’s lead candidates are advancing through clinical trials, with emerging data suggesting improved patient outcomes, while its AI platform is now positioned to generate revenue through commercial licensing agreements.
The Phase 2 HARMONIC™ trial evaluating LP-300 in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment produced encouraging results. Emerging data showed that the progression-free survival benefit of LP-300 deepened with longer treatment duration in patients harboring EGFR exon 21 L858R mutations. The U.S. Food and Drug Administration (FDA) reviewed key protocol amendments without objection, allowing the trial to proceed as planned. These findings underscore the potential of LP-300 to address a significant unmet need in this specific patient population.
In the European Union, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. Additionally, the U.S. Patent and Trademark Office issued a Notice of Allowance for a three-gene patient-selection signature associated with LP-184, strengthening the company’s intellectual property portfolio and enabling more precise patient selection in future trials.
In August, Lantern took a strategic step by establishing OMAI as a wholly owned subsidiary. The company entered into board-approved commercial licensing agreements for its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. This move aligns with Lantern’s goal to transform cancer drug development by leveraging AI, and it introduces a new revenue stream for the company.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined by 42% to approximately $1.8 million, reflecting increased efficiency in trial execution. The net loss was approximately $7.1 million, or $0.57 per share, compared to $4.3 million, or $0.40 per share, in the prior-year quarter. The increase was largely due to approximately $3.6 million in warrant-related expense. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling approximately $7.4 million.
Lantern’s clinical pipeline includes LP-184, LP-284, and LP-300, with LP-184 also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned subsidiary. The company’s AI platform, RADR®, continues to guide its precision oncology efforts. With the establishment of OMAI and the commercial availability of withZeta.ai, Lantern is positioning itself at the forefront of AI-driven drug discovery, offering subscription-based research tools to the global biomedical community. This strategic pivot not only advances its internal pipeline but also creates potential for external partnerships and revenue diversification.
